Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy

Abstract

Our data demonstrate the feasibility and tolerability of intrathecal treatment with nusinersen in adults with SMA type 2 and type 3. However, treatment can be medically and logistically challenging, particularly in patients with SMA type 2 and in patients with spondylodesis.